Table 1.
Baseline characteristics of the 609 patients included in the APROCO-COPILOTE genetic sub-study according to CCR5 genotype
| Characteristics | wt/wt (n=512) | Δ32/wt (n=97) | p | ||
|---|---|---|---|---|---|
| Male gender | N (%) | 409 (80) | 79 | (81) | 0.72 |
| Age (years) | median (IQR) | 37 (32–43) | 38 | (33–46) | 0.05 |
| Primary risks for HIV infection | N(%) | 0.03 | |||
| Injection drug use | 87 (17) | 8 | (8) | ||
| Place of birth | N(%) | 0.0020 | |||
| Europe | 366 (71) | 85 | (88) | ||
| Africa | 68 (13) | 3 | (3) | ||
| Other | 24 (5) | - | |||
| Missing data | 54 (11) | 9 | (9) | ||
| Year of first HAART | N (%) | 0.68 | |||
| 1997 | 247 (48) | 49 | (51) | ||
| 1998–1999 | 265 (52) | 48 | (49) | ||
| AIDS stage | N (%) | 114 (22) | 20 | (21) | 0.72 |
| CD4+ cell count (/mm3) | median (IQR) | 265 (119–403) | 321 | (156–466) | 0.06 |
| HIV-RNA (log10 copies/ml) | median (IQR) | 4.5 (3.7–5.2) | 4.3 | (3.6–4.7) | 0.02 |
| No prior antiretroviral treatment | N (%) | 226 (44) | 43 | (44) | 0.97 |